<DOC>
	<DOCNO>NCT01815294</DOCNO>
	<brief_summary>The purpose study support qualification replacement manufacture site DOXIL/CAELYX ( doxorubicin HCL ) .</brief_summary>
	<brief_title>A Pivotal Bioequivalence Study DOXIL/CAELYX ( Doxorubicin HCL ) Patients With Advanced Refractory Solid Malignancies Including Patients With Ovarian Cancer</brief_title>
	<detailed_description>This randomize ( individual assign random order study treatment sequence ) , open-label ( identity assign treatment sequence know ) , single dose , 2-cycle , crossover ( patient receive treatment random order ) bioequivalence study DOXIL/CAELYX ( doxorubicin HCL ) patient advanced refractory solid malignancy ( include patient ovarian cancer ) . This study adaptive 2-stage design . Bioequivalence base encapsulate doxorubicin test end Stage 1 use data least 24 ovarian cancer patient . An interim analysis free doxorubicin perform end Stage 1 use data 42 patient cancer type . The study may continue Stage 2 additional patient cancer type ; final evaluation bioequivalence free doxorubicin perform end Stage 2 . The study include screen phase follow open-label treatment phase consist 2 doxorubicin treatment cycle end-of-treatment visit Cycle 3 , Day 1 . Participants may enter optional extension phase 2 cycle . Safety monitor throughout study . Blood sample pharmacokinetic analysis obtain participant specify time 29 day start study drug administration Cycles 1 2 determination plasma concentration encapsulate free doxorubicin .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Diagnosed advanced refractory solid malignancy : histologically cytologically confirm advanced ovarian cancer fail platinumbased chemotherapy ; histologically cytologically confirm metastatic breast cancer fail approve lifeprolonging therapy ; histologically cytologically confirm solid malignancy metastatic unresectable , standard treatment long option Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Recovered acute toxicity prior treatment ( exemption : alopecia , grade1 neuropathy ) Prior doxorubicin ( anthracyclines ) cumulative dose &lt; =360 mg/m2 cumulative epirubicin dose &lt; =720 mg/m2 ( calculate use doxorubicin equivalent dos : 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 0.3 mg mitoxantrone = 0.25 mg idarubicin ) Adequate liver , bone marrow , renal function accord protocoldefined parameter Left ventricular ejection fraction ( LVEF ) within normal limit institution determine multiple uptake gate acquisition ( MUGA ) echocardiography Agrees protocoldefined use effective contraception Negative pregnancy test screening ( applicable woman child bear potential ) within 7 day prior start treatment Positive history know brain metastasis leptomeningeal disease ( patient brain metastasis enrol follow condition meet : treat stable &gt; 4 week [ &gt; 2 week SRS/Cyberknife ] ; evidence progression hemorrhage treatment ; steroid treatment discontinue least 2 week prior first administration doxorubicin ; enzyme induce antiepileptic drug discontinue least 4 week first administration doxorubicin History hypersensitivity reaction doxorubicin HCl component DOXIL/CAELYX Any major surgery , radiotherapy , immunotherapy within last 21 day ( limited palliative radiation allow &gt; =2 week prior first dose ; &gt; =4 week whole brain radiotherapy ) ; chemotherapy regimens delay toxicity within last 4 week ( within last 6 week prior nitrosourea mitomycin C ) ; chemotherapy regimens give continuously weekly basis limit potential delayed toxicity within last 2 week Use investigational drug within 21 day 5 halflives ( whichever short ) prior first dose doxorubicin Unstable angina myocardial infarction within precede 12 month ; congestive heart failure history uncontrolled cardiac disease &gt; Class II base New York Heart Association Criteria Has infection either uncontrolled infection , clinically important ( occur within 4 week prior first dose study agent ) , require current systemic intravenous treatment Uncontrolled concurrent illness include , limited , poorly control hypertension diabetes , psychiatric illness/social situation may potentially impair patient 's compliance study procedure Concomitant use strong CYP3A4 inhibitor ( clarithromycin , diltiazem , erythromycin , itraconazole , ketoconazole , nefazodone , ritonavir , telithromycin verapamil ) strong CYP3A4 inducer ( carbamazepine , phenobarbital , phenytoin , rifampin St John 's wort ) least 4 week first dose doxorubicin Cycle 1 completion pharmacokinetic sampling Cycle 2 Has condition , opinion investigator , would make participation best interest ( eg , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment Woman pregnant , breastfeeding , plan become pregnant man plan father child enrol study within 3 month last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Solid malignancy</keyword>
	<keyword>Advanced refractory solid malignancy</keyword>
	<keyword>Metastatic cancer</keyword>
	<keyword>DOXIL/CAELYX</keyword>
	<keyword>Doxorubicin HCL</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>